Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Ehninger

Showing results (301-310 of 403) with videos related to

Pageof 41
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 studyMarkus Schaich, Christoph Röllig, Silke Soucek, et al.
British Journal of Haematology|October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)Martin Wermke, Claudia Schuster, Florian Nolte, et al.
Cancer Management and Research|February 25, 2022
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of RelapseKatja Sockel, Friedrich Stölzel, Franziska Hönl, et al.
Annals of Hematology|November 5, 2014
Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trialChristoph Röllig, Kerstin Schäfer-Eckardt, Matthias Hänel, et al.
Blood|January 26, 2017
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemiaTilmann Bochtler, Martin Granzow, Friedrich Stölzel, et al.
Lancet (London, England)|August 11, 2012
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised studyHannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, et al.
The New England Journal of Medicine|May 9, 2014
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantationRoy F Chemaly, Andrew J Ullmann, Susanne Stoelben, et al.
Plos One|January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyUtz Krug, Anja Koschmieder, Daniela Schwammbach, et al.
British Journal of Haematology|March 5, 2025
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AMLSebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Pageof 41

Showing results (301-310 of 403) with videos related to

Sort By:
Pageof 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 studyMarkus Schaich, Christoph Röllig, Silke Soucek, et al.
British Journal of Haematology|October 8, 2016
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS)Martin Wermke, Claudia Schuster, Florian Nolte, et al.
Cancer Management and Research|February 25, 2022
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of RelapseKatja Sockel, Friedrich Stölzel, Franziska Hönl, et al.
Annals of Hematology|November 5, 2014
Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trialChristoph Röllig, Kerstin Schäfer-Eckardt, Matthias Hänel, et al.
Blood|January 26, 2017
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemiaTilmann Bochtler, Martin Granzow, Friedrich Stölzel, et al.
Lancet (London, England)|August 11, 2012
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised studyHannes Wandt, Kerstin Schaefer-Eckart, Knut Wendelin, et al.
The New England Journal of Medicine|May 9, 2014
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantationRoy F Chemaly, Andrew J Ullmann, Susanne Stoelben, et al.
Plos One|January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyUtz Krug, Anja Koschmieder, Daniela Schwammbach, et al.
British Journal of Haematology|March 5, 2025
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AMLSebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.
Pageof 41